AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the pharmaceutical ...

Regeneron Pharmaceuticals intends to advance two blood-thinning drugs into Phase 3 testing next year after mid-stage study results showed they matched or surpassed marketed medicines at preventing ...

Dec. 31, 2024 – Jan. 22, 2025 • New York, New York ...

Dec. 24, 2024 – Dec. 31, 2024 • New York, New York ...

Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...

Ally Schott felt lonely when she was diagnosed with endometriosis at the age of 12. With few treatment options and limited information to go on, she and her family had to become self-taught medical ...

Merck & Co. has made its first big move in obesity treatment, announcing Wednesday it is paying Hansoh Pharma $112 million for rights outside China to a preclinical pill that works similarly to the ...

One year on from the landmark U.S. approval of two powerfully effective gene therapies for sickle cell disease, the treatments have been barely used, a sluggish start that reflects the myriad ...

Vertex Pharmaceuticals lost more than $15 billion in value Thursday as new data on its closely watched pain drug disappointed Wall Street. The medication is meant to be a non-addictive alternative to ...

The Food and Drug Administration has identified additional safety concerns associated with use of a drug used to treat a rare liver condition in the latest sign of trouble for a medicine once seen as ...

Today, a brief rundown of news involving Ionis Pharmaceuticals and the Food and Drug Administration, as well as updates from Zealand Pharma, Sangamo Biosciences and Novartis that you may have missed.

Almost 15 years ago, in the midst of an opioid epidemic that would kill more than half a million people in the U.S., a startup formed with the aim of creating new, non-addictive pain drugs. This goal ...